STERIS (NYSE:STE) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of STERIS (NYSE:STE – Free Report) from a buy rating to a strong-buy rating in a report published on Saturday morning,Wall Street Zen reports.

Other equities analysts also recently issued reports about the company. Piper Sandler reaffirmed an “overweight” rating and set a $275.00 price target (up from $270.00) on shares of STERIS in a research report on Friday, August 7th. UBS Group lowered their price objective on STERIS from $275.00 to $270.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Weiss Ratings upgraded STERIS from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday, November 9th. Morgan Stanley upgraded STERIS from an “overweight” rating to a “buy” rating in a research note on Friday. Finally, KeyCorp upped their target price on STERIS from $269.00 to $284.00 and gave the company an “overweight” rating in a research report on Friday, November 6th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, STERIS currently has an average rating of “Moderate Buy” and an average price target of $283.50.

Check Out Our Latest Research Report on STE

STERIS Stock Down 0.9%

NYSE:STE opened at $261.84 on Friday. The company’s 50-day simple moving average is $224.02 and its 200-day simple moving average is $224.61. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.44 and a current ratio of 2.05. STERIS has a fifty-two week low of $195.14 and a fifty-two week high of $269.44. The stock has a market capitalization of $25.43 billion, a P/E ratio of 23.27 and a beta of 0.86.

STERIS (NYSE:STE – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The medical equipment provider reported $2.94 EPS for the quarter, topping the consensus estimate of $2.68 by $0.26. The firm had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.56 billion. STERIS had a net margin of 13.41% and a return on equity of 14.80%. STERIS’s revenue was up 8.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.47 EPS. On average, equities analysts anticipate that STERIS will post 11.46 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 17th. Investors of record on Tuesday, November 17th will be paid a $0.69 dividend. The ex-dividend date is Tuesday, November 17th. This represents a $2.76 dividend on an annualized basis and a yield of 1.1%. STERIS’s dividend payout ratio (DPR) is 32.74%.

Insider Buying and Selling

In other STERIS news, CFO Karen L. Burton sold 5,880 shares of the company’s stock in a transaction that occurred on Wednesday, November 11th. The shares were sold at an average price of $255.62, for a total transaction of $1,503,045.60. Following the transaction, the chief financial officer owned 12,956 shares in the company, valued at approximately $3,311,812.72. This represents a 31.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Mohsen Sohi sold 4,893 shares of the firm’s stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $253.22, for a total transaction of $1,239,005.46. Following the completion of the transaction, the director directly owned 24,305 shares of the company’s stock, valued at approximately $6,154,512.10. This represents a 16.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 1.12% of the stock is owned by company insiders.

Institutional Investors Weigh In On STERIS

A number of large investors have recently made changes to their positions in the stock. Western Wealth Management LLC purchased a new position in STERIS in the 1st quarter worth $25,000. Compass Financial Management LLC purchased a new stake in STERIS during the 3rd quarter valued at about $25,000. Elevation Wealth Partners LLC grew its stake in STERIS by 1,130.0% during the 2nd quarter. Elevation Wealth Partners LLC now owns 123 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 113 shares during the last quarter. Trust Co. of Vermont purchased a new stake in STERIS during the 2nd quarter valued at about $41,000. Finally, Community Financial Services Group LLC grew its stake in STERIS by 50.0% during the 3rd quarter. Community Financial Services Group LLC now owns 216 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 72 shares during the last quarter. 94.69% of the stock is owned by hedge funds and other institutional investors.

About STERIS

(Get Free Report)

STERIS plc (NYSE: STE) provides infection prevention and procedural products and services for healthcare, pharmaceutical, research, and other industries. Its offerings include sterilizers, washers and other equipment used to clean and sterilize medical devices and surgical instruments, as well as products for operating rooms and endoscopy procedures. The company also provides equipment installation, maintenance, repair, and training, along with contract sterilization and laboratory testing services.

Further Reading

Analyst Recommendations for STERIS (NYSE:STE)

Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.